Trial Profile
Daxas in COPD Therapy
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 03 Nov 2016
Price :
$35
*
At a glance
- Drugs Roflumilast (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- Acronyms DINO
- Sponsors Takeda; Takeda Pharmaceuticals International GmbH
- 04 May 2012 Takeda Global Research and Development Center added as company and lead trial centre as reported by ClinicalTrials.gov.
- 30 Jan 2011 Status changed from not yet recruiting to recruiting according to a ClinicalTrials.gov record.
- 28 Jan 2011 New trial record